

Ultragenyx Pharmaceutical Inc.  
Form FWP  
January 29, 2014

**Filed Pursuant to Rule 433**

**Issuer Free Writing Prospectus dated January 29, 2014**

**Relating to Preliminary Prospectus dated January 17, 2014**

**Registration No. 333-192244**

This free writing prospectus relates only to the offering described below and should be read together with the preliminary prospectus dated January 17, 2014 relating to this offering (the Preliminary Prospectus ), included in Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-192244) relating to this offering. The most recent amendment to such Registration Statement can be accessed through the following link <http://www.sec.gov/Archives/edgar/data/1515673/000119312514014673/d601113ds1a.htm>

The following information is intended to update and supplement the information contained in the Preliminary Prospectus.

<b>Common stock offered:</b>	4,838,710 shares
<b>Underwriters option to purchase additional shares:</b>	725,806 shares
<b>Common stock outstanding after this offering:</b>	28,140,212 shares (or 28,866,018 shares if the underwriters exercise in full their option to purchase additional shares)
<b>Expected initial public offering price per share:</b>	Between \$19.00 and \$20.00 per share
<b>Net Proceeds:</b>	We estimate that the net proceeds from our issuance and sale of 4,838,710 shares of our common stock in this offering will be approximately \$84.7 million, based on an assumed initial public offering price of \$19.50 per share (the midpoint of the expected price range for the offering), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional shares, we estimate that the net proceeds from this offering will be approximately \$97.9 million.

**Ultragenyx Pharmaceutical Inc. has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (SEC) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents Ultragenyx has filed with the SEC for more complete information about Ultragenyx and this offering. You may get these documents for free by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov). Alternatively, Ultragenyx, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204 or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; telephone: 866-718-1649; email: [prospectus@morganstanley.com](mailto:prospectus@morganstanley.com).**

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form FWP

border-bottom-width: 1">

(Street)

CORAL GABLES, FL 33134 4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
---------------------------------	--------------------------------------	--	--------------------------------	---	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
Options to purchase common stock	\$ 3.54	05/29/2018		A	166,666	05/29/2019 05/29/2025	Common Stock 166,666
Options to purchase common stock	\$ 3.54	05/29/2018		A	166,667	05/29/2020 05/29/2025	Common Stock 166,667
Options to purchase common stock	\$ 3.54	05/29/2018		A	166,667	05/29/2021 05/29/2025	Common Stock 166,667

purchase  
common  
stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MCENANY PATRICK J 355 ALHAMBRA CIRCLE, SUITE 1250 CORAL GABLES, FL 33134	X		President and CEO	

## Signatures

/s/ Patrick J.  
McEnany

05/31/2018

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.